12/08/2021 - Press release
A study led by doctors and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), and CIBER Oncology (CIBERONC) has demonstrated the role a protein, neuregulin, plays in generating resistance to the most common treatment for HER2-positive breast cancer, one of the most aggressive types. The study, published in the journal Clinical Cancer Research, and in which leading Italian researchers Luca Gianni from the Fondazione Gianni Bonnadonna and Giampaolo Bianchini from the IRCCS Ospedale San Raffaele have collaborated, has identified that in patients with high levels of this protein, the success rate with the monoclonal antibody trastuzumab, the first-line drug, drops. Conversely, when combined with another monoclonal antibody, pertuzumab, the situation is reversed and full pathological response levels are restored.
06/08/2021 - Press release
A Hospital del Mar project to determine new prognostic and predictive markers that could be beneficial in metastatic small cell lung cancer treatment, using genetic analysis techniques, has been awarded $200,000 from the Oncomine Clinical Research Grant programme, promoted by the US-based multinational biotech company Thermo Fisher Scientific, which supports research that enables advances in the field of molecular patient profiling, with the aim of improving clinical outcomes. The research was led by Dr. Edurne Arriola, head of the lung cancer section in the Medical Oncology Service and a researcher at the Hospital del Mar Medical Research Institute (IMIM), and Dr. Beatriz Bellosillo, head of the Medical Oncology Service and also an IMIM researcher. To undertake the project, they will analyse samples from 300 patients with this pathology, collected over the last 10 years. The research will focus on evaluating the potential of the liquid biopsy technique, which can detect DNA from tumour cells in the blood, to monitor the disease and its evolution, as well as detecting potential biomarkers of treatment benefit and predictors of long-term prognosis.
Més informació "$200,000 grant for lung cancer research at Hospital del Mar"
Combining chemotherapy with a BRAF oncogene inhibitor proves effective at treating this disease. The study, published in the journal Oncogene, was led by researchers from the Hospital del Mar Medical Research Institute, Hospital del Mar and CIBERONC. This alternative paves the way towards a new approach for patients affected by this type of tumor, which has no cure in the most advanced stages or cases of relapse.
Més informació "A new approach to metastatic melanoma discovered"
21/06/2021 - Press release
As a result of the collaboration between research centres in Italy and Spain, the PEGASUS study has been launched with the aim of demonstrating that, thanks to the liquid biopsy guidance tool, it is possible to increase the precision of post-surgical treatment for colon cancer patients. The Vall d'Hebron Institute of Oncology (VHIO), part of the Vall d'Hebron Campus, and the Hospital del Mar Medical Research Institute (IMIM), both in Barcelona; and the INCLIVA Health Research Institute at Hospital Clínico in Valencia, are the three Spanish centres taking part in this project. The study was instigated by Dr. Silvia Marsoni, from the FIRC Institute of Molecular Oncology (IFOM) in Milan, and is supported by the AIRC Foundation within the 5x1000 programme, which is coordinated by Prof. Alberto Bardelli of the University of Turin and the Institute of Candiolo FPO-IRCCS.
19/05/2021 - Press release
Liquid biopsy can predict which patients with localised rectal cancer are likely to relapse, even after initial chemotherapy and radiotherapy treatment, and prior to surgery. This is supported by a study led by doctors and researchers from the Medical Oncology and Pathology Departments at Hospital del Mar, as well as the Hospital de Mar Medical Research Institute (IMIM) and the CIBER in cancer (CIBERONC), which has been published in the American Association for Cancer Research journal, Clinical Cancer Research. The study analysed samples from 72 patients from twenty hospitals in Spain, taken as part of the GEMCAD1402 clinical trial conducted by the Spanish Multidisciplinary Group on Digestive Cancer.
Més informació "Liquid biopsy can predict relapse in patients with locally advanced rectal cancer"
13/05/2021 - Press release
Hospital del Mar-IMIM is leading an international clinical trial to evaluate the performance and suitability of new equipment for locating the sentinel lymph node in prostate cancer patients. The new tool is a flexible, miniaturized probe, which should improve the detection of a marker (a radioactive molecule) injected into the patient to locate the first node the tumour drains to. The technology SENSEI®, has been developed by the UK company Lightpoint Medical with the support of the Hospital del Mar Urology Service.
16/12/2020 - Press release
T-cell acute lymphoblastic leukaemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis. A collaborative project between IRB Barcelona's Biomedical Genomics lab, headed by ICREA researcher Núria López-Bigas, Anna Bigas' group at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), and Josep Maria Ribera's lab at the Josep Carreras Leukaemia Research Institute (IJC) has discovered that the cells responsible for resistance to T-ALL treatment in adults are already present in the tumours before diagnosis.
29/10/2020 - Press release
The Hospital del Mar Medical Research Institute (IMIM), together with the INCLIVA Health Research Institute, from Hospital Clínic in Valencia, and the Vall d'Hebron Institute of Oncology, have obtained funding from the Spanish Association Against Cancer (AECC) for their project entitled Factors derived from the tumoral microenvironment in localised colon cancer: clinical impact and therapeutic implications. Dr. Clara Montagut, head of the Gastrointestinal Cancer Unit in the Medical Oncology Service at Hospital del Mar, coordinator of the Clinical and Translational Research Group on new therapies and biomarkers in colon and rectal cancer at the Hospital del Mar Medical Research Institute (IMIM) and a participant in the study, points out that "The goal of this research is to identify markers that will help us determine whether the cancer will re-emerge in a patient who has undergone colon cancer surgery. This is extremely important for people who have colon cancer, since at present we are unable to predict whether the tumour will reappear or not after surgery.
19/10/2020 - Press release
Last Friday, the FERO Foundation announced the winners of the 19th FERO Grants and the winner of the 2nd FERO-Mango Breast Cancer Research Project. The grants, worth €80,000 each, are intended to help young researchers develop their translational cancer research projects over a two-year period. "It is expected that 277,394 people will be diagnosed with cancer before the end of 2020. We cannot allow the pandemic scenario in which we find ourselves to detract from the treatment and survival opportunities of the thousands of patients who are currently struggling with cancer. That is why at FERO we are doing everything we can to ensure that COVID-19 affects doctors and patients as little as possible, and that resources continue to reach researchers and centres. One way of achieving this is by continuing to support projects through our grants", explains Sol Daurella, president of the institution.
05/06/2020 - Press release
Detecting the best research talents and providing these people with financial, structural and stability means advancing in cancer care via translational research projects that improve treatment and diagnosis through innovation with clinical application. This is the ambitious goal of the innovative and cutting-edge I CRIS Research Programmes promoted by CRIS against cancer, which have already received their first awards thanks to a meticulous evaluation and selection process led by a prestigious committee of international experts. Over the next five years, the three winning projects will focus on colorectal cancer (the second-ranked cancer in terms of deaths) prostate cancer (diagnosed in 1.3 million people each year), and immunotherapy, a highly innovative type of treatment that is changing the outlook of many cancers. "Research is our life and only through research are we going to find a cure for cancer. With the CRIS Research Programmes we want to detect the best research talent and provide these people with financial and work-related peace of mind. We want to discover and support the Nobel Prize winners of tomorrow and these first CRIS Programmes are just the beginning. In the next edition we will double the number of winners, underlining our commitment to research in spite of the current situation we are experiencing",explains Diego Megía, president of CRIS against cancer.
Més informació "Dr. Clara Montagut, awarded a I CRIS Programme of Excellence in Cancer Research"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
